Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)
Status:
Terminated
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole
Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral
sclerosis.